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Facioscapulohumeral muscular dystro-
phy (FSHD), was one of the first diseases
shown to be caused by an unstable repeat
in the early 1990s along with spinal and
bulbar muscular atrophy (SBMA), myo-
tonic dystrophy (DM1), and fragile X
mental retardation (FRAXA), where the
latter three are caused by genetically
expanding trinucleotide repeats [1]. How-
ever, FSHD differs considerably from the
trinuclotide repeat diseases, as it is caused
by a contraction of a macrosatellite (D4Z4
repeat, 3.3 kb/unit). Moreover, far less is
understood about the pathogenic mecha-
nism for FSHD, relative to SBMA, DM1,
and FRAXA. This is not due to a shortage
of experimental efforts, plausible hypoth-
eses, or collaborative efforts towards un-
derstanding FSHD [2,3]. The elucidation
of FSHD is hampered by the size of the
unstable repeat, its sequence complexity,
the number of repeat units, and the
presence of the repeat on Chromosomes
4 and 10, making analysis technically
difficult. The difficulty is compounded
further by the absence of an obvious gene,
transcript, or protein in the unstable or
proximal region; in fact, the D4Z4 repeats
have been referred to as ‘‘junk’’ DNA or
are thought to be a pseudogene, at best. As
a result, FSHD has proved to be one of the
most complex and challenging genetic
diseases to even a glimpse an underlying
pathogenic cause for FSHD. Several
recent papers, including one in this issue
of PLoS Genetics [4], have made significant
advances that now permit us to expand
our understanding of FSHD pathogenesis,
a repeat contraction disease.
FSHD presents with weakness of facial
muscles, stabilizers of the scapula, or
dorsiflexors of the foot. The weakness is
progressive with age. Disease severity is
highly variable and shows some signs of
anticipation, common to other repeat-
associated diseases. FSHD is autosomal
dominant, characterized by a deletion of
D4Z4 repeat units, located in the sub-
telomere of chromosome 4q35 (Figure 1).
Non-affected D4Z4 alleles are polymor-
phic having 11–100 repeat units; individ-
uals affected with FSHD have 10 or fewer
units, but must have at least one unit to
show disease, which is now known to be
the most telomeric unit. D4Z4 contrac-
tions can be inherited or occur as de novo
mutations. The contracted D4Z4 repeat
arrays show loss of DNA methylation and
reduced histone 3 lysine 9 trimethylation,
consistent with a more open chromatin
structure [5]. The role of the altered
chromatin in FSHD pathogenesis is con-
troversial and has been suggested to
enhance expression of adjacent genes like
FRG1 or ANT1 [6]. More recently,
FSHD2-affected individuals that display
the altered chromatin but have non-
contracted D4Z4 repeats have implicated
the derepression of a DUX4 transcript
encoded on the D4Z4 repeat units [7,8].
However, the mechanism through which
the altered chromatin at D4Z4 repeats
contributes to FSHD remains unclear.
DUX4 Transcripts from the D4Z4
Repeats
The distal (most telomeric) unit of the
D4Z4 repeat was recently shown to have a
transcriptional profile that differs from
internal units, and the transcript extended
into telomeric regions [9,10,11]. This
finding suggests that this very last, distal
D4Z4 unit may be the keyunitthat mustbe
retained after D4Z4 contractions to lead to
disease (Figure 1). The DUX4 transcript
from the distal D4Z4 unit is suggested to
encode a double homeobox gene of
unknown function, related to DUXC and
Duxbl, which in mice is expressed in germ-
line cells and in early phases of skeletal
muscle development.Previously, Tapscott’s
group showed full-length RNA transcripts
from the D4Z4 repeat spanning the DUX4
open reading frame, DUX4-fl, as well as a
shorter transcript, DUX4-s, that utilized a
cryptic splice donor, which retains the
double-homeobox domains but loses the
carboxyterminal end of DUX4 [11]. When
expressed in cultured cells, the full length
DUX4 caused reduced proliferation, in-
duced morphological changes, increased
sensitivity to oxidative damage, MyoD-
repression, impaired myogenesis, and, at
higher levels, led to cell death—all features
compatible with observations in FSHD1
patient cells [11,12]. This distal DUX4
transcript can be observed in FSHD1
patient myotubes but not in control myo-
tubes [13]. Exactly what mediates the
expression in FSHD has proved elusive.
Genetics Reveals a Role of a
Polyadenylation Variant
Downstream of the Most-
Telomeric Chromomosome 4
D4Z4 Unit
Recent genetic advances made by a
group of international labs, headed by
Silvere van der Maarel, revealed the most-
telomeric D4Z4 unit and its adjacent
polyadenylation sequence to be crucial to
FSHD pathogenesis [13] (Figure 1).
Some Chromosome 4 backgrounds are
categorized as permissive for FSHD dis-
ease or non-permissive to FSHD when
D4Z4 contracts. Chromosome 10 repeats
are typically non-permissive. Essentially,
D4Z4 contractions to 1–10 units on
permissive chromosomes are pathogenic,
while contractions on non-permissive
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quence comparison of the permissive
chromosomes with the common, non-
permissive chromosomes failed to reveal
a motif unique to the proximal D4Z4 units
of the repeat array that might explain the
permissiveness of the 4A161 chromosome
[13]. Curiously, immediately distal to the
most-telomeric D4Z4 unit, there was a
polymorphism unique to the permissive
4A161 chromosome. This sequence poly-
morphism was subsequently shown to act
as polyadenylation signal (ATTAAA) of
the distal (most telomeric) DUX4 tran-
script. Notably, all permissive, but not
non-permissive, chromosomes harbored
the efficient poly(A) signal [9,13]. This
association should be investigated further.
Several rare, but highly informative
FSHD individuals were identified that
harbored unusual contracted hybrid
D4Z4 repeats composed of D4Z4 units
from Chromosome 4 and Chromosome
10—some hybrids resided on Chromo-
some 4, others on Chromosome 10 [13].
Two important conclusions can be made
from these individuals. First, the cause of
FSHD disease linked to Chromosome 10
excludes a previously suggested role for
enhanced expression of the adjacent genes
on 4q (FRG1, FRG2, ANT1, etc….) in the
pathogenesis of FSHD [6], as these were
not present on Chromosome 10. Secondly,
in all affected individuals with the unusual
hybrid repeats, the last D4Z4 unit of the
contracted array originated from a per-
missive background and had the adjacent
highly efficient polyadenylation motif,
thereby strengthening the crucial role of
this motif to FSHD pathogenesis.
In transfection experiments DUX4 tran-
scripts derived from the permissive chro-
mosome were stable and efficiently poly-
adenylated, whereas transcripts derived
from non-permissive chromosomes were
undetectable and polyadenylation ineffi-
cient [13]. Thus, a bona fide poly(A) signal
unique to the permissive chromosomes
produced stable transcripts with greater
polyadenylation efficiency than non-per-
missive chromosomes, thereby providing
strong evidence suggesting that increased
polyadenylation, and hence stability, of the
distal (most telomeric) DUX4 transcript
may be causally implicated in FSHD
pathogenesis (Figure 1). Despite lacking
the polyadenylation motif that is present
only on the FSHD permissive chromo-
some, testis (but not muscle cells) are able
to express and stably retain the DUX4
transcript. Snider et al. [4] revealed that
alternative polyadenylation arises at motifs
more telomeric on the non-permissive and
permissive chromosomes in testis, but not
somatic cells. They suggest that this
DUX4 alternative polyadenylation may
be regulated in a tissue- and development-
specific manner. This important advance
revealed that DUX4 transcript and pro-
tein was naturally expressed and provided
insight into how this expression was
regulated, as well as avenues to how it
could be misregulated in disease states.
Analysis of a broader range of tissues and
developmental stages will reveal insight
into the function of DUX4.
Epigenetics May Regulate DUX4
Splicing
The full-length RNA transcripts from
the D4Z4 repeat spanning the DUX4 open
Figure 1. Simplified schematic outlining the genetic requirements for FSHD and the
current model for pathogenesis. The Chromosome 4 D4Z4 repeats (open triangles) and its
homolog on Chromosome 10 (closed triangles), indicating the 4qA/4qB polymorphisms that
define the genetic background of the repeat. Individuals with FSHD have a D4Z4 repeat tract of
,11 repeats, at least 1 unit on 4qA but not on 4qB or 10q chromosomes. All permissive
chromosomes and FSHD individuals have a distal canonical highly efficient poly(A) motif ATTAAA.
Non-permissive chromosomes have inefficient degenerate motifs. Both have alternative poly(A)
motifs further downstream. Current model involving contraction, DUX4 transcription, polyade-
nylation, altered chromatin, regulated DUX4 splicing, tissue- and development-specific DUX-fl
protein expression. See text for details. Lower, de-differentiation and differentiation affect DUX4-fl
expression in control but not FSHD cells. See text for details.
doi:10.1371/journal.pgen.1001180.g001
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transcript, DUX4-s that utilized a cryptic
splice donor produce full-length and
truncated DUX4 proteins, respectively
[11]. The presence of the full-length
DUX4-fl mRNA in control human testes,
but not in control muscle, which express
the shorter DUX4-s mRNA, was shown
by Snider et al. to be mediated by DUX4
splice site usage in this issue of PLoS
Genetics [4]. Some FSHD samples also
expressed DUX4-s transcript. Thus, both
control and FSHD myoblasts and muscles
transcribe DUX4, but the full-length
DUXF-fl transcript is expressed only in
FSHD cells and muscles. Expression of
DUX4-fl, but not DUX4-s, can lead to
both nuclear foci and increased apoptosis
[4]. However, overexpression of either
DUX4-fl or DUX4-s will suppress myo-
genesis [11,12]. Understanding the natural
function of the DUX4-fl protein and the
DUX4-s protein, presuming its careful
regulation supports a function, is now a
pressing issue in FSHD research. Curious-
ly, the relatively high levels of DUX4
expression in FSHD cells appears to be
due to large numbers of transcripts
produced in a small subset of cells, rather
than a small number of transcripts pro-
duced in most cells. Understanding what
regulates non-expression or expression in
cells may provide insight into disease
pathogenesis and possibly avenues for
therapeutically down-regulating DUX4 ex-
pression in FSHD individuals. Similar
insights may arise from understanding
what regulates the splicing of the DUX4
transcript.
Snider et al. [4] suggest that DUX4
splice site usage may be regulated by
epigenetic modifications of the D4Z4
region (Figure 1). Control fibroblasts
expressed DUX4-s, but not DUX4-fl;
however, when these cells were made into
induced pluripotent stem cells (iPS) they
switched to expression of DUX4-fl
(Figure 1, lower portion). Upon differen-
tiation of these control iPS cells, expression
switched back from DUX4-fl to DUX4-s.
This switch correlated with increased
levels of repressive chromatin modification
(H3K9me3) at the D4Z4 repeats in the
differentiated cells. In contrast, in FSHD
fibroblasts, their iPS derived cells, and
their differentiated stages, DUX4-fl was
consistently expressed. Thus, it appears
that higher levels of repressive chromatin
at the D4Z4 region in control cells may
mediate the splicing that produces DUX4-
s. Similarly, the reduced levels of repres-
sive chromatin present in FSHD cells [5]
may suppress the production of DUX4-s
and allow expression of DUX4-fl.
In conclusion, D4Z4 repeats are not
junk DNA: DUX4 encoded in the repeats
is in fact a retrogene, most likely retro-
transposed to a DNA gene from the
DUXC mRNA [10]. Tapscott and col-
leagues have shown DUX4 is normally
expressed in the male germline, and for
the FSHD-permissive variant, the DUX4
transcript is efficiently polyadenylated in
muscle, thus suggesting that DUX4 is not a
‘‘defective’’ pseudogene. Importantly, the
aberrant suppression of DUX4-fl protein
expression in muscle, both by transcript
stabilization via disease-permissive polyad-
enylation and suppressed splicing to the
shortened DUX4-s variant, seems to be
important contributors to FSHD patho-
genesis. The mechanisms through which
the DUX4 transcripts and proteins lead to
normal development or FSHD are future
goals waiting to be expanded upon in this
macrosatellite contracting disease.
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